LAWRENCE BLATT - 25 Oct 2023 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Chief Executive Officer, Director
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Lawrence M. Blatt
Issuer symbol
ALGS
Transactions as of
25 Oct 2023
Net transactions value
+$500,000
Form type
4
Filing time
27 Oct 2023, 16:14:22 UTC
Previous filing
12 Sep 2023
Next filing
28 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALGS Common Stock Award $461,858 +610,277 +49% $0.7568 1,847,575 25 Oct 2023 Direct
holding ALGS Common Stock 113,423 25 Oct 2023 See footnote F1
holding ALGS Common Stock 122,601 25 Oct 2023 See footnote F2
holding ALGS Common Stock 18,517 25 Oct 2023 See footnote F3
holding ALGS Common Stock 18,517 25 Oct 2023 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Warrants (Right to Buy) Award $38,142 +305,138 $0.1250* 305,138 25 Oct 2023 Common Stock 305,138 $0.7568 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Lawrence M. Blatt Living Trust dated 8/27/14.
F2 PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA.
F3 Zachary David Blatt Irrevocable Trust dated 8/24/14.
F4 Zoe Anne Blatt Irrevocable Trust dated 8/24/14.